Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Main Inclusion Criteria: * Diagnosis and history of chronic, moderate-to-severe AD (by the Eichenfield revised criteria of Hanifin and Rajka) for at least 3 years before the screening visit. * Subjects who have an AD flare at the start of the trial (EASI score ≥10 at screening and ≥16 at the baseline visit). Main Exclusion Criteria: * Treatment with allergen immunotherapy within 6 months before the baseline visit. * Treatment with leukotriene inhibitors, systemic glucocorticoids, or other systemic treatment for AD (including immunosuppressive treatment, ultraviolet therapy, and biologics) within 4 weeks before the baseline visit. * Treatment with topical corticosteroids or topical calcineurin inhibitors within 1 week before the baseline visit. * Chronic or acute infection requiring treatment with oral or intravenous antibiotics, anti-virals, anti-parasitics, anti-protozoals, or anti-fungals within 4 weeks before the screening visit or superficial skin infections within 1 week before the screening visit. * History of malignancy within 5 years before the baseline visit, with the following exceptions: subjects with a history of completely treated carcinoma in situ of cervix, and non-metastatic squamous or basal cell carcinoma of the skin are allowed. * Hypertension (\>150/95 mmHg) at the screening visit. * Planned surgical procedure during the length of the subject's participation in this trial. * Use of a tanning booth/parlour within 4 weeks before the screening visit. * Pregnant, breastfeeding, or lactating women. * Laboratory abnormalities at the screening visit.